Key Takeaways VKTX is running two Phase III trials, VANQUISH-1 and VANQUISH-2, for its obesity drug VK2735.VANQUISH-1 enrolled about 4,650 patients, beating targets only months after the study began.VKTX plans to finish enrolling nearly 1,100 patients in VANQUISH-2 by the end of this quarter.Viking Therapeutics (VKTX) is one of the few companies with a late-stage obesity candidate in its pipeline. The company is developing VK2735, an investigational novel, dual GLP-1 and GIP receptor agonist (RA), in multip ...